Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Haematology and transfusion indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Macrocytosis without anaemia

Haematology and transfusion · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Time-critical presentation

Isolated macrocytosis is rarely an emergency, but acute neurological deficits, rapidly progressive gait or weakness, suspected nitrous-oxide toxicity, haemolysis with renal or cardiovascular compromise, blasts, severe neutropenia with fever, thrombocytopenic bleeding or newly evolving pancytopenia requires same-day assessment. Do not wait for anaemia before treating strongly suspected neurological B12 deficiency.

Overview

Confirm isolated macrocytosis, distinguish megaloblastic, regenerative, toxic, hepatic, endocrine and clonal patterns, and decide when observation, causal treatment or haematology referral is appropriate.

Macrocytosis means an MCV above the laboratory's appropriate reference interval. It may precede anaemia because enlarged cells can circulate while total red-cell mass remains adequate. Mechanisms divide into impaired DNA synthesis, altered membrane composition, larger reticulocytes, marrow dysplasia and artefact. The history should cover diet, alcohol quantity and dependence, liver and thyroid disease, gastrointestinal surgery, malabsorption, bleeding, jaundice, pregnancy, family history, nitrous oxide and medicines including hydroxycarbamide, methotrexate, antiretrovirals, antiseizure and cytotoxic treatment.

The film and reticulocyte count turn a numerical finding into a physiological pattern. Macro-ovalocytes and hypersegmented neutrophils support B12 or folate deficiency. Round macrocytes and target cells suggest alcohol or liver disease. Polychromasia with raised absolute reticulocytes suggests bleeding, haemolysis or recovery. Dysplastic neutrophils, abnormal platelets, monocytosis or additional cytopenias raise myelodysplasia. The analyser can be misleading with cold agglutinins, severe hyperglycaemia, delayed processing or a mixed red-cell population, so laboratory discussion is appropriate when the result is implausible.

Aetiology

01

Nutritional and malabsorptive causes

Vitamin B12 or folate deficiency, autoimmune gastritis, coeliac disease and gastrointestinal surgery can enlarge red cells before haemoglobin falls.

02

Alcohol and liver disease

Direct alcohol marrow toxicity, nutritional deficiency, altered membrane lipids and chronic liver disease commonly produce non-megaloblastic macrocytosis.

03

Medicines and treatment effects

Hydroxycarbamide, methotrexate, selected antiretrovirals, antiseizure medicines and cytotoxic therapy change DNA synthesis or marrow maturation in recognisable contexts.

04

Regenerative and marrow disorders

Reticulocytosis after bleeding or haemolysis, hypothyroidism, myelodysplastic syndromes and other marrow disease enlarge average cell volume through different mechanisms.

Pathophysiology

  1. 1
    Cell size increases

    Impaired DNA synthesis, altered membrane composition or release of larger reticulocytes increases the measured mean corpuscular volume before red-cell mass necessarily declines.

  2. 2
    The analyser reports an average

    MCV combines all circulating red cells, so mixed microcytes and macrocytes, transfused cells or a small abnormal population can conceal the true morphology.

  3. 3
    Compensation preserves haemoglobin

    Marrow output and red-cell survival may initially maintain circulating haemoglobin despite abnormal maturation, toxic exposure or increased cell size.

  4. 4
    Progression reveals the mechanism

    Continuing deficiency, liver disease, haemolysis or clonal marrow failure eventually changes reticulocytes, other lineages, film morphology, symptoms or haemoglobin.

Clinical features and red flags

Megaloblastic morphology

Macro-ovalocytes, hypersegmented neutrophils, low reticulocytes, glossitis or neurological features supports B12 or folate-related impaired DNA synthesis.

Alcohol or hepatic pattern

Regular excess alcohol, round macrocytes, target cells, abnormal liver tests, stigmata of liver disease or nutritional risk supports toxic or hepatic causes.

Regenerative pattern

Raised absolute reticulocytes and polychromasia after bleeding, haemolysis or treatment indicate larger young cells rather than primary megaloblastosis.

Clonal warning patternRed flag

Progressive MCV, dysplastic neutrophils, abnormal platelets, monocytosis, additional cytopenias or constitutional symptoms raises a marrow neoplasm and requires specialist review.

Neurological disease without anaemiaRed flag

Paraesthesia, proprioceptive loss, gait disturbance, weakness, cognition or visual change can represent urgent B12 deficiency despite preserved haemoglobin.

Investigations

  1. 01
    Repeat FBC, prior counts and peripheral filmFirst step
    Why
    Confirm persistence, expose mixed cells and detect dysplasia or artefact.
    Interpretation and limitations
    A stable isolated rise differs from progressive multilineage change. Macro-ovalocytes, target cells, polychromasia, hypersegmentation, dysplasia and analyser flags direct distinct pathways.
  2. 02
    Absolute reticulocyte count
    Why
    Separate regeneration from underproduction or maturation failure.
    Interpretation and limitations
    A raised result supports bleeding, haemolysis or recovery. A low or normal response with megaloblastic morphology directs B12 and folate assessment; interpret after recent transfusion or treatment carefully.
  3. 03
    Vitamin B12 and folate
    Why
    Identify treatable megaloblastic deficiency before anaemia or neurological progression.
    Interpretation and limitations
    Use NICE NG239 thresholds and functional markers when B12 is indeterminate or nitrous oxide is involved. Establish B12 safety before giving folate alone.
  4. 04
    Liver profile, thyroid function and alcohol assessment
    Why
    Find common non-megaloblastic and reversible causes.
    Interpretation and limitations
    Laboratory abnormalities support but do not quantify alcohol harm or prove causation. Review dependence and withdrawal risk; mild liver or thyroid abnormalities may coexist with another mechanism.

Differential diagnosis

01

Laboratory artefact

Cold agglutinins, marked hyperglycaemia, delayed sample processing and extreme leucocytosis can produce a spurious high MCV that disappears with laboratory-directed repeat handling.

02

Physiological or baseline variation

Pregnancy, neonatal age and a stable individual baseline can shift cell size, but interpretation still uses the correct reference interval and previous counts.

03

Early megaloblastic deficiency

Macro-ovalocytes, hypersegmented neutrophils, glossitis, neurological features or B12 and folate risks favour impaired DNA synthesis before anaemia develops.

04

Regeneration after loss

Polychromasia and raised absolute reticulocytes following haemorrhage, haemolysis or effective treatment show that larger young cells explain the average.

05

Clonal marrow disease

Progressive MCV, dysplastic cells, neutropenia, thrombocytopenia, monocytosis or unexplained constitutional symptoms supports specialist investigation for myelodysplasia or another neoplasm.

Management

01VerifyConfirm a real isolated abnormalityFirst stepMCV is above the laboratory reference interval while haemoglobin remains within range.+
  1. 1Compare previous FBCs, all lineages, RDW and sampling context, review the film and discuss cold agglutinins, delayed processing or other analyser artefact with the laboratory when appropriate.
  2. 2First lineFirst-line assessment combines absolute reticulocytes, B12, folate, liver and thyroid tests with alcohol, diet, surgery, nitrous oxide, bleeding and complete medicine history.
  3. 3EscalationEscalate neurological features, haemolysis, blasts, dysplasia or additional cytopenias immediately rather than scheduling routine observation.
02Treat causeFollow the mechanism-specific routeNutritional, toxic, regenerative, endocrine, hepatic or medicine-related macrocytosis is supported.+

Complications

01

Missed neurological B12 disease

Reassurance from normal haemoglobin can delay cobalamin replacement while peripheral nerve, posterior-column, cognitive or visual injury progresses.

02

Progressive marrow failure

Early myelodysplastic or infiltrative disease may begin with isolated macrocytosis before anaemia, infection risk or bleeding from additional cytopenias emerges.

03

Unrecognised alcohol-related harm

Treating MCV as an incidental number can miss dependence, withdrawal risk, malnutrition, liver injury and safeguarding or social needs.

04

Delayed haemolysis diagnosis

Reticulocyte-driven macrocytosis may be the first clue to compensated red-cell destruction, which can later cause anaemia, jaundice, gallstones or renal complications.

05

Unnecessary treatment

Empirical folate or B12 without adequate assessment can obscure the mechanism, create false reassurance and leave medicine toxicity or clonal disease unrecognised.

Monitoring and follow-up

  • Trend MCV, haemoglobin, white-cell differential and platelets together, because a new second-lineage abnormality changes the referral threshold.
  • Record neurological findings and review promptly if paraesthesia, gait, weakness, vision or cognition changes while B12 assessment or treatment is underway.
  • For a medicine-associated pattern, document the expected effect, responsible specialty and triggers for dose or diagnostic review rather than simply ignoring flagged results.
  • For alcohol-related macrocytosis, monitor intake goals, withdrawal safety, nutrition, liver disease and wider psychosocial risk rather than using MCV as a sobriety test.
  • When observation is chosen, specify the repeat FBC interval and name who will review it; stable values still need symptom safety-netting.
  • Re-refer or escalate if macrocytosis progresses, anaemia develops, reticulocytes become abnormal or dysplasia and additional cytopenias appear.

Special situations

MCV is a population mean

A normal or high average can hide two opposing cell populations. RDW and film often reveal more than the headline number.

Reticulocytes are naturally larger

Compensated haemolysis or recent bleeding may raise MCV before haemoglobin falls, making regeneration an important cause of isolated macrocytosis.

Neurology outranks the FBC

B12-related nerve injury can occur without anaemia or macrocytosis. Objective symptoms should activate the diagnostic and treatment pathway.

Expected does not mean unexplained

Hydroxycarbamide or antiretroviral treatment may predict macrocytosis, but new cytopenias, symptoms or film abnormalities still require assessment.

Observation is an active plan

A stable unexplained result can be followed safely only when interval, ownership, warning symptoms and referral triggers are explicit.

Common pitfalls

  1. 01

    Reassuring a patient solely because haemoglobin is normal.

  2. 02

    Treating MCV rather than identifying its mechanism.

  3. 03

    Giving empirical folate before assessing B12 and neurological symptoms.

  4. 04

    Ignoring reticulocytes and missing compensated haemolysis or recent bleeding.

  5. 05

    Attributing every abnormality to alcohol or a known medicine without film review.

  6. 06

    Repeating blood tests indefinitely without ownership or escalation criteria.

  7. 07

    Missing myelodysplasia when additional cytopenias or dysplasia emerge.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Haematology and transfusionOriginal SBA

Macrocytosis with normal haemoglobin

A patient has isolated macrocytosis, numb feet and impaired proprioception, but haemoglobin is normal. Which action is most appropriate?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Haematology and transfusion topics →
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG239 vitamin B12 deficiency recommendationsNeurological recognition without anaemia, diagnostic thresholds and treatment urgency.
  • BNF anaemias treatment summaryUK treatment context for B12 and folate-related macrocytosis.
  • NHS vitamin B12 or folate deficiency anaemiaSymptoms, causes and neurological complications of haematinic deficiency.
  • NICE NG12 suspected cancer recommendations by findingReferral context for unexplained cytopenias and suspected haematological malignancy.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom

Management targets the cause rather than cell size. Neurological B12 disease is treated promptly through NICE NG239 even without anaemia. Folate is replaced only after B12 safety is established. Alcohol-related macrocytosis prompts non-judgemental assessment, withdrawal-risk planning and liver and nutritional care. A necessary medicine may be continued when macrocytosis is expected and other abnormalities are absent; changing chemotherapy, antiretroviral or antiseizure therapy requires specialist coordination. Stable unexplained macrocytosis can be monitored, but progression or lineage change triggers renewed investigation.

Key points

  • Confirm that macrocytosis is persistent and genuine by reviewing the laboratory reference range, prior counts, film and pre-analytical flags; MCV is an average, not a diagnosis.
  • Normal haemoglobin does not exclude clinically important B12 deficiency. Ask about paraesthesia, gait, vibration and joint position, cognition, visual symptoms, diet, metformin, surgery and nitrous oxide.
  • Separate megaloblastic morphology, with macro-ovalocytes and hypersegmented neutrophils, from round macrocytes or target cells in alcohol and liver disease and polychromasia in regeneration.
  • Use absolute reticulocytes early. A raised result redirects the assessment towards recent bleeding, haemolysis or marrow recovery rather than a primary maturation defect.
  • Review alcohol and every medicine explicitly. Hydroxycarbamide and some antiretrovirals can cause expected macrocytosis, but a known medicine does not explain new cytopenias automatically.
  • Check B12, folate, liver and thyroid tests and use cause-directed haemolysis studies. Mixed iron deficiency can normalise MCV or produce a high RDW and dimorphic film.
  • Progressive macrocytosis, dysplasia, monocytosis or additional cytopenias warrants haematology discussion and sometimes bone marrow assessment for myelodysplastic or infiltrative disease.
  • If evaluation is reassuring and the count is stable, observation is reasonable only with a named interval, symptom safety-net and responsibility for reviewing repeat results.
  • 05
    Haemolysis profile
    Why
    Identify compensated destruction when reticulocytes are raised.
    Interpretation and limitations
    Combine bilirubin, LDH, haptoglobin, DAT and film. One abnormal marker is insufficient, and intravascular, extravascular, immune and mechanical patterns require different follow-up.
  • 06
    Specialist marrow assessment
    Why
    Investigate progressive unexplained macrocytosis, dysplasia or additional cytopenias.
    Interpretation and limitations
    Haematology selects molecular, flow or marrow tests according to the film and count pattern; stable isolated macrocytosis without warning features may be monitored first.
    • 1
    PreferredTreat B12 promptly when neurological disease is suspected; for folate deficiency, the preferred sequence establishes B12 safety before folic acid is given.
  • 2Address alcohol with withdrawal-risk and liver support, treat thyroid or hepatic disease, and investigate bleeding or haemolysis when reticulocytes are raised.
  • 3AlternativeFor a necessary medicine, an alternative is continued therapy with monitoring when isolated macrocytosis is expected; specialist review precedes changing chemotherapy, antiretroviral or antiseizure regimens.
    • 03Observe or referClose the loop on unexplained macrocytosisInitial assessment finds no cause and the patient has no emergency feature.+
    1. 1If stable and isolated with a reassuring film, arrange a defined repeat FBC and symptom review, recording the clinician responsible for acting on progression.
    2. 2PreferredThe preferred referral route is haematology for rising MCV, evolving anaemia or other cytopenias, dysplasia, abnormal cells, monocytosis, splenomegaly or constitutional symptoms.
    3. 3EscalationEscalate persistent unexplained progression for specialist molecular or bone marrow assessment rather than repeating the same haematinic panel indefinitely.